Compare Repligen Corporation Common Stock (RGEN) vs Roku Inc. Class A Common Stock (ROKU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Roku Inc. Class A Common Stock — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Roku Inc. Class A Common Stock trades at $152.43 (market cap $22.67B). The key difference: Roku Inc. Class A Common Stock is far larger — about 2× Repligen Corporation Common Stock's market cap, and Repligen Corporation Common Stock is more actively traded (1,259,263 versus 1,039,228). Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Roku Inc. Class A Common Stock for 6 Days on average.
| RGEN | ROKU | |
|---|---|---|
Market Cap | $11.14B | $22.67B |
Volume | 1,259,263 | 1,039,228 |
Sector | Health | Media |
52-Week High | $194.57 | $159.76 |
52-Week Low | $102.87 | $82.93 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $11.02B | $20.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Roku trades at $152.66, down slightly by 0.1% today. The stock shows mixed technical signals with a neutral overall rating. Fundamentally, revenue growth is solid with 2026 projections at $5.2B, while profitability improved significantly with net income margin rising to 6.81%. Recent earnings beats and the pending Fox acquisition approval highlight positive momentum. Analyst consensus is evenly split between Buy and Hold with a $161.38 price target.
Outlook remains cautiously optimistic with strong earnings performance and acquisition synergies offering upside potential. Key risks include regulatory scrutiny of the Fox deal, competitive pressures in streaming, and negative cash flow trends. The stock presents a growth opportunity if execution continues, but investors should monitor acquisition progress and profitability sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Roku Inc. Class A Common Stock
Roku operates a streaming platform that combines its operating system, streaming devices, TV partnerships, and advertising services. It connects viewers with streaming content and services.
Read more on ROKU →
